|
Agent (μg/mouse)
|
Day of agent administration
|
Tumor weight (average ± SE) (mg)
|
Body weight (average ± SE) (g)
|
Heart weight (average ± SE) (mg)
|
|---|
|
Experiment 1 (assessment of tumor weight: day 28)
|
|
PBS
|
3
|
491.1 ± 68.4**
|
ND
|
ND
|
|
ZOL (80 μg)
|
3
|
0**
|
ND
|
ND
|
|
Experiment 2 (assessment of tumor weight: day 28)
|
|
PBS
|
3
|
384.8 ± 36.8**
|
15.9 ± 5.1**
|
99.8 ± 5.2*
|
|
ZOL (40 μg)
|
3
|
19.8 ± 7.2**
|
18.9 ± 0.24**
|
114.5 ± 3.6*
|
|
Experiment 3 (assessment of tumor weight: day 35)
|
|
PBS
|
3
|
197.7 ± 22.9**
|
18.5 ± 1.0
|
123.2 ± 5.8
|
|
ZOL (40 μg)
|
3
|
2.5 ± 1.2**
|
19.6 ± 0.3
|
129.5 ± 3.5*
|
|
ZOL (15 μg)
|
3
|
79.3 ± 13.2**
|
19.2 ± 0.2
|
116.6 ± 3.4*
|
|
Experiment 4 (assessment of tumor weight: day 28)
|
|
PBS
|
10
|
377.9 ± 13.3*
|
16.1 ± 0.4*
|
ND
|
|
ZOL (40 μg)
|
10
|
188.6 ± 62.1*
|
19.2 ± 0.5*
|
ND
|
- BALB/c nude mice were inoculated with human mesothelioma, MSTO-211H cells (experiment 1, 2 and 4) or EHMES-10 (experiment 3) (1 × 106/mouse), in the intrapleural cavity and were injected with PBS or ZOL (100 μl in volume) on day 3 or 10. Tumor weights were measured on the indicated day and the averages with standard errors are shown (experiment 1; n = 5, experiment 2; n = 6, experiment 3; n = 7, experiment 4; n = 7)
- ** P < 0.01; * P < 0.05 (experiment 3; difference of tumor weights is statistically significant in any of two groups and that of heart weights is statistically significant only between ZOL 15 μg- and ZOL 40 μg-injected groups)
